Home

ABOUT

Editorial

PRESS RELEASES

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

HomeEvox Therapeutics to Expand Its Work on Cell-targeted Delivery of Nucleic Acid-based...

Evox Therapeutics to Expand Its Work on Cell-targeted Delivery of Nucleic Acid-based Drugs

Evox Therapeutics Ltd, a leading exosome therapeutics company, today announces that it has secured an undisclosed amount of funding from the Bill & Melinda Gates Foundation. The funds will be used to support the Company’s development of cell-targeted exosome-based approaches to more effectively deliver a nucleic acid-based anti-infective drug.

Evox Therapeutics is engineering exosomes, the body’s natural vesicular delivery system, to enable a wide variety of drugs to reach previously inaccessible tissues and compartments, such as crossing the blood-brain barrier to deliver drugs to the central nervous system, intracellular delivery of biologics, and extra-hepatic delivery of RNA therapeutics.

Dr. Antonin de Fougerolles, Chief Executive Officer of Evox, commented: “We are pleased to be working with the Bill & Melinda Gates Foundation to maximize the effectiveness of their therapeutic drug through cell- and tissue-targeted exosome-mediated delivery. The foundation has a reputation for working with partners that can drive meaningful change – this funding is a testament to the quality of our platform and its potential application in areas of high medical need.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

By using this website you agree to accept Medical Device News Magazine Privacy Policy